BRTX - BioRestorative Therapies, Inc.
1.7
0.000 -0.006%
Share volume: 38,128
Last Updated: 04-07-2025
Healthcare/Services – Health:
1.03%
PREVIOUS CLOSE
CHG
CHG%
$1.70
0.00
0.00%
Fundamental analysis
34%
Profitability
25%
Dept financing
6%
Liquidity
33%
Performance
50%
Company vs Stock growth
vs
233.600 K
43.300 K
-190.300 K
-81.46%
1.640
1.810
0.170
10.37%
Performance
5 Days
-5.56%
1 Month
10.39%
3 Months
-0.58%
6 Months
3.03%
1 Year
32.81%
2 Year
-52.58%
Key data
Stock price
$1.70
DAY RANGE
$1.58 - $1.72
52 WEEK RANGE
$1.03 - $2.55
52 WEEK CHANGE
$32.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
Company detail
CEO: Lance Alstodt
Region: US
Website: biorestorative.com
Employees: 7
IPO year: 2011
Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services
Region: US
Website: biorestorative.com
Employees: 7
IPO year: 2011
Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services
The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies in August 2011.
Recent news
BioRestorative Therapies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
BioRestorative Therapies ( NASDAQ:BRTX ) Full Year 2024 Results Key Financial Results Net loss: US$8.98m (loss narrowed...
Read more